The short-term prognosis analysis of papillary thyroid carcinoma under the pre- and post-operation changes of#br# serum thyroglobulin(Tg) and BRAFV600E gene mutation
LI Shuang, LIU Bao-ping, CHANG Wei, WANG Rui-hua, XIE Xin-li, CHENG Bing, HAN Xing-min, RUAN Qiao
Department of Nuclear Medicine, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
Abstract：Objective: To explore the short-term efficacy and prognosis analysis of 131I papillary thyroid carcinoma patients under the pre- and post-operation changes of serum thyroglobulin(Tg) and BRAFV600E gene mutation. Methods: Seventy-eight patients of papillary thyroid carcinoma were enrolled to measure the Tg and TgAb value one week before and one month after operation. Meanwhile, the patients were monitored after operation to figure out whether there was BRAFV600E gene mutation. The standards for good short-term efficacy and prognosis include less than 2 ng/mL Tg under stimulated state and negative results of neck Doppler ultrasound and whole body radioactive iodine scanning. Results: Among the 43 patients with a reduced post-operative Tg value compared with one week before operation, there were 6 patients(13.9％) with recurrence after 131I operation in half a year. Among the 35 patients with an increased or similar post-operative Tg value compared with pre-operation, there were 24 patients(68.6％) with recurrence after 131I operation in half a year. There was significant difference between two groups(P<0.05). Among the 53 patients with positive BRAFV600E gene mutation, there were 28 patients(49.1％) with recurrence after 131I operation in half a year. Among the 25 patients with negative BRAFV600E gene mutation, there were 4 patients(16.0％) with recurrence after 131I operation in half a year. There was significant difference between two groups(P<0.05). Among the 21 patients with a reduced post-operative Tg value compared with one week before operation and with negative BRAFV600E gene mutation, there were 2 patients(9.5％) with recurrence after 131I operation in half a year. Among the 32 patients with an increased or similar post-operative Tg value compared with pre-operation and positive BRAFV600E gene mutation, there were 23 patients(71.9％) with recurrence after 131I operation in half a year. There was significant difference between two groups(P<0.05). Conclusion: The prognosis of papillary thyroid carcinoma seems poor with no decreased post-operative Tg value or positive BRAFV600E gene mutation.
李 霜，刘保平，常 伟，王瑞华，谢新立，程 兵，韩星敏，阮 翘. 术前及术后Tg值变化及BRAFV600E突变在甲状腺乳头状癌#br# 近期预后的预测分析[J]. 中国临床医学影像杂志, 2017, 28(1): 15-18.
LI Shuang, LIU Bao-ping, CHANG Wei, WANG Rui-hua, XIE Xin-li, CHENG Bing, HAN Xing-min, RUAN Qiao. The short-term prognosis analysis of papillary thyroid carcinoma under the pre- and post-operation changes of#br# serum thyroglobulin(Tg) and BRAFV600E gene mutation. JOURNAL OF CHINA MEDICAL IMAGING, 2017, 28(1): 15-18.
[1]武汉医学院，中山医学院. 外科病理学[M]． 下册. 武汉：湖北人民出版社，1983：846-859.
[2]Degeorgla MA, Deegaonkar A． Multimodal monitoring in the neurological intensive care unit[J]． Neurologist, 2005, 11(1): 45-54．
[3]Mazzaferrl EL, Jhing SM. long-time impact of initial surgical and medical therapy on papillary and follicular thyroid calleer[J]． Am J Med, 1994, 95(5): 418-428．
[4]Pacini F, Castaglla MG, Brim L, et al． Differentiated thyroid cancer: ESM0 clinical recommendations for diagnosis, treatment and follow-up[J]． Ann Oncol, 2004, 19(Suppl 2): ii99-ii101．
[5]Verburg FA, Aktolun C, Chiti A, et al. Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer[J]. Eur J Nucl Med Mol Imaging, 2016, 43(6): 1-5.
[6]Jung KW, Park S, Kong HJ, et al. Cancer statistics in Korea: incidence, mortality and survival in 2006-2007[J]． J Kor Med Sci, 2010, 25(8): 1113-1121.
[7]Nascimento C, Borget I, Troalen F, et al. Ultrasensitive serum thyroglobulin measurement is useful for the follow-up of patients treated with total thyroidectomy without radioactive Iodine ablation[J]． Eur J Endocrinol, 2013, 169(5): 689-693.
[8]Rinaldi S, Plummer M, Biessy C, et al． Thyroid-stimulating hormone, thyroglobulin, and thyroid hormones and risk of differentiated thyroid carcinoma: the EPIC study[J]． J Nat Cancer Inst, 2014, 106(6): 284-290.
[9]Ronga G, Filesi M, Ventroni G, et al． Value of the first serum thyroglobulin level after total thyroidectomy for the diagnosis of metastases from differentiated thyroid carcinoma[J]． Eur J Nucl Med, 1999, 26(11): 1448-1452.
[10]任艳鑫，隋军，李晓江，等. 血清Tg、TGAB与分化型甲状腺癌关系的临床分析[J]. 现代肿瘤医学，2008，16（9）：1488-1489.
[11]Xing M． BRAF mutation in thyroid cancer[J]． Endocr Relat Cancer, 2005, 12(2): 245-262．
[12]Elisei R, Ugolini C, Viola D, et al． BRAFV600E mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study[J]． J Clin Endocrinol Metab, 2008, 93(10): 3943-3949．
[13]Cuan H, Ji M, Bao RR, et al． Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer[J]． J Clin Endocrinol Metab, 2009, 94(5): 1612-1617．
[14]Frasca F, Nucera C, Pellegriti G, et al． BRAF(V600E) mutation and the biology of papillary thyroid cancer[J]． Endocr Relat CarIcer, 2008, 15(1): 191-205．
[15]Mian C, Barollo S, Pennelli G, et al． Molecular characteristics in papillary thyroid cancers(PTCs) with no(131)I uptake?[J]． Clin Endocrinol(Oxf), 2008, 681(1): 108-116．
2017, Vol. 28 
